Creon in HIV Patients With Steatorrhea

NCT00623025 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2011-08-01

No results posted yet for this study

Summary

The study investigates the effect of pancreatic enzymes on steatorrhea in HIV patients.

Conditions

  • Steatorrhea

Interventions

DRUG

Creon 25000

6 to 9 capsules Creon 25000 per day

DRUG

Placebo

6 to 9 capsules placebo per day

Sponsors & Collaborators

Principal Investigators

  • Suntje Sander, PhD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Romania

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623025 on ClinicalTrials.gov